BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26675757)

  • 21. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells.
    Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H
    Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
    Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
    Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
    Maréchal R; Van Laethem JL
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
    Pineda DM; Rittenhouse DW; Valley CC; Cozzitorto JA; Burkhart RA; Leiby B; Winter JM; Weber MC; Londin ER; Rigoutsos I; Yeo CJ; Gorospe M; Witkiewicz AK; Sachs JN; Brody JR
    Cancer Biol Ther; 2012 Aug; 13(10):946-55. PubMed ID: 22785201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
    Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
    J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
    Shimamoto N; Ito M; Chiba M; Honma S; Imazu H; Sumiyama K
    Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):478-485. PubMed ID: 32265136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
    J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Palam LR; Gore J; Craven KE; Wilson JL; Korc M
    Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells.
    Yong-Xian G; Xiao-Huan L; Fan Z; Guo-Fang T
    J Cancer Res Ther; 2016 Oct; 12(Supplement):1-4. PubMed ID: 27721241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.